Get the Stockscreener App
25.68
2.94%
-0.74
Olema Pharmaceuticals Inc stock is traded at $25.68, with a volume of 75,856.
It is down -2.94% in the last 24 hours and down -7.32% over the past month.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
See More
Previous Close:
$26.42
Open:
$26.05
24h Volume:
75,856
Relative Volume:
0.02
Market Cap:
$2.06B
Revenue:
-
Net Income/Loss:
$-96.66M
P/E Ratio:
-11.94
EPS:
-2.15
Net Cash Flow:
$-83.73M
1W Performance:
-5.51%
1M Performance:
-7.32%
6M Performance:
+450.30%
1Y Performance:
+338.36%
1-Day Range:
$25.53
$26.18
1-Week Range:
$25.53
$27.86
52-Week Range:
$2.86
$36.26
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Name
Olema Pharmaceuticals Inc
Sector
Industry
Phone
(415) 651-3316
Address
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
25.70 | 2.12B | 0 | -96.66M | -83.73M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.58 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.82 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
830.94 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
363.26 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
341.94 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Initiated | Piper Sandler | Overweight |
| Oct-08-25 | Initiated | Guggenheim | Buy |
| Aug-12-25 | Reiterated | Citigroup | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Jan-30-24 | Initiated | Citigroup | Buy |
| Jul-21-23 | Initiated | Oppenheimer | Outperform |
| May-05-23 | Initiated | CapitalOne | Overweight |
| Feb-22-23 | Initiated | Credit Suisse | Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-28-22 | Initiated | H.C. Wainwright | Neutral |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Dec-14-20 | Initiated | Canaccord Genuity | Buy |
| Dec-14-20 | Initiated | Cowen | Outperform |
| Dec-14-20 | Initiated | JP Morgan | Overweight |
| Dec-14-20 | Initiated | Jefferies | Buy |
View All
Olema Pharmaceuticals Inc Stock (OLMA) Latest News
Olema Pharmaceuticals (NASDAQ:OLMA) Director Cyrus Harmon Sells 10,000 Shares - MarketBeat
Harmon Cyrus, director at Olema, sells $268,800 in stock - Investing.com
Harmon Cyrus, director at Olema, sells $268,800 in stock By Investing.com - Investing.com South Africa
Does US Foods Holding Corp stock benefit from AI growthPortfolio Return Summary & Real-Time Market Trend Scan - baoquankhu1.vn
Olema Pharmaceuticals (NASDAQ:OLMA) Director Cyrus Harmon Sells 3,489 Shares - MarketBeat
A Look At Olema Pharmaceuticals (OLMA) Valuation After Fresh Bullish Analyst Coverage And Conference Spotlight - Sahm
Olema Pharmaceuticals director Harmon sells $101k in stock By Investing.com - Investing.com Nigeria
Olema Pharmaceuticals director Harmon sells $101k in stock - Investing.com
Insider Sell Alert: Kovacs Shane William Charles Sells Shares of Olema Pharmaceuticals Inc (OLMA) - GuruFocus
Wall Street Remains Bullish on Olema Pharmaceuticals Inc. (OLMA) - Insider Monkey
Insider Selling: Olema Pharmaceuticals (NASDAQ:OLMA) Insider Sells 3,822 Shares of Stock - MarketBeat
Olema Pharma CFO Kovacs sells shares worth $2.98 million By Investing.com - Investing.com South Africa
Insider Selling: Olema Pharmaceuticals (NASDAQ:OLMA) Insider Sells 100,000 Shares of Stock - MarketBeat
Olema Pharma CFO Kovacs sells shares worth $2.98 million - Investing.com
Olema Pharma ch. discov. Myles sells shares worth $2.97 million By Investing.com - Investing.com Nigeria
David Myles Sells 50,000 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Insider David Myles Sells 10,000 Shares - MarketBeat
Olema Pharma ch. discov. Myles sells shares worth $2.97 million - Investing.com
Stop Loss: Is Olema Pharmaceuticals Inc forming bullish engulfing patternsJuly 2025 Closing Moves & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Will Olema Pharmaceuticals Inc. stock pay special dividendsGlobal Markets & Intraday High Probability Alerts - Bộ Nội Vụ
Aug Rallies: What are analysts price targets for Olema Pharmaceuticals IncJuly 2025 Highlights & Real-Time Volume Surge Alerts - baoquankhu1.vn
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
OLMA stock jumps 10% into JPMorgan week — what to watch for Olema Pharmaceuticals - TechStock²
Assessing Olema Pharmaceuticals (OLMA) Valuation After Analyst Upgrades And Recent Fundraising - Sahm
Olema Pharmaceuticals stock jumps 10% into JPM conference week: what OLMA traders are watching next - TechStock²
How Olema Pharmaceuticals Inc. stock performs during Fed tightening cycles2025 Year in Review & AI Enhanced Market Trend Forecasts - Улправда
Buy Signal: Will Olema Pharmaceuticals Inc. stock gain from government policiesMarket Sentiment Review & Weekly Top Gainers Alerts - Улправда
Cashing In at the Peak: Olema Pharmaceuticals Insiders Sell $8 Million in Stock After 300% Surge - FinancialContent
Olema Insider Sells $8 Million in Shares After 300% Stock Surge - Yahoo Finance
Olema Insider Sells $8 Million in Shares After 300% Stock Surge - The Motley Fool
Olema Pharmaceuticals (NASDAQ:OLMA) Raised to Strong-Buy at UBS Group - MarketBeat
How Bullish Analyst Coverage and New Capital Raise Could Impact Olema Pharmaceuticals (OLMA) Investors - Yahoo Finance
Olema Pharmaceuticals, Inc.Common Stock (NQ: OLMA - FinancialContent
Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Down 8.6%Here's What Happened - MarketBeat
Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High? - MSN
Pfizer collaboration with Olema may spark future bidding waranalyst - MSN
UBS Initiates Coverage on Olema Pharmaceuticals (OLMA) with a 'B - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Coverage Initiated by Analysts at Piper Sandler - MarketBeat
Piper Sandler initiates Olema Pharmaceuticals stock with Overweight rating By Investing.com - Investing.com Canada
UBS initiates Olema Pharmaceuticals stock with Buy rating, $45 target By Investing.com - Investing.com Canada
Olema Oncology (OLMA) Targeted for Growth with $60 Price Objecti - GuruFocus
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Olema Oncology reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Olema Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Biotech Olema gives 8 new employees long-term stock option deals - Stock Titan
Insider Selling: Olema Pharmaceuticals (NASDAQ:OLMA) Director Sells 2,881 Shares of Stock - MarketBeat
Olema Pharmaceuticals director Harmon sells $82,194 in stock By Investing.com - Investing.com Nigeria
Olema Pharmaceuticals Inc Stock (OLMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.22%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):